Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
Global Benign Prostatic Hyperplasia (BPH) Testing market size was valued at USD 2.1 billion in 2024 and is projected to grow at a CAGR of 5.8% from 2025 to reach USD 3.2 billion by 2031. The market growth is driven by the rising prevalence of BPH among aging male populations and advancements in diagnostic technologies.
Benign Prostatic Hyperplasia refers to non-cancerous prostate gland enlargement that commonly affects men over 50 years old. This condition causes urinary symptoms including frequent urination, weak urine stream, and incomplete bladder emptying. The prostate-specific antigen (PSA) test remains the gold standard screening method, though newer diagnostic approaches like urinary biomarkers and advanced imaging are gaining traction.
The market expansion is further supported by increasing healthcare expenditure, greater awareness of men's health issues, and favorable reimbursement policies in developed nations. North America currently dominates the market due to its advanced healthcare infrastructure, while Asia-Pacific shows the highest growth potential because of improving diagnostic capabilities and rapidly aging populations in countries like Japan and China.
Aging Population and Rising BPH Prevalence
The global increase in aging male population is a primary driver for the Benign Prostatic Hyperplasia (BPH) testing market. Studies indicate that approximately 50% of men in their 60s and 90% of men in their 70s experience BPH symptoms. This demographic shift creates sustained demand for diagnostic solutions.
Advancements in Diagnostic Technologies
Innovations in non-invasive testing methods, including digital rectal examination (DRE) improvements, PSA blood tests, and ultrasound technologies are driving market growth. The development of portable ultrasound devices and improved urinalysis systems are particularly noteworthy.
The global BPH testing market is projected to grow at a CAGR of 5.3% from 2023 to 2030, driven by technological advancements in diagnostic equipment and increasing healthcare expenditure.
Increased awareness campaigns by urological associations and pharmaceutical companies about early BPH detection are contributing to higher testing rates worldwide.
MARKET CHALLENGES
Limited Reimbursement Policies
In many developing regions, insurance coverage for BPH diagnostic tests remains limited, creating affordability barriers. Even in developed markets, reimbursement rates for newer diagnostic methods often lag behind their adoption.
Other Challenges
Diagnostic Accuracy Concerns
Current PSA tests have specificity challenges, with approximately 25% of men with elevated PSA levels showing negative biopsy results, leading to unnecessary procedures and patient anxiety.
Cultural Barriers to Testing
In some regions, social stigma around prostate health and reluctance to undergo digital rectal exams limits testing adoption, particularly in conservative demographics.
High Cost of Advanced Diagnostic Systems
The significant capital investment required for modern urodynamic testing equipment and high-resolution ultrasound systems limits their adoption in resource-constrained healthcare settings. Many facilities in developing nations continue to rely on basic diagnostic methods.
Competition from Alternative Therapies
The growing popularity of pharmacological treatments for BPH symptoms without prior diagnostic confirmation may reduce testing volumes, particularly in markets where direct-to-consumer advertising is permitted for BPH medications.
Emerging Markets Expansion
Asia-Pacific and Latin American markets present significant growth opportunities due to improving healthcare infrastructure and increasing medical awareness. China and India are expected to show particularly strong growth in BPH testing volumes.
Point-of-Care Testing Development
The development of rapid, office-based diagnostic tests for BPH could revolutionize testing protocols, reducing the need for multiple specialist visits and enabling earlier intervention.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
PSA Blood Test remains the most widely adopted diagnostic method due to its established clinical protocols and non-invasive nature. However, emerging urodynamic tests are gaining traction for their ability to provide comprehensive bladder function assessments. Cystoscopy methods are typically reserved for severe cases requiring direct visualization of the urinary tract. |
| By Application |
|
Hospitals dominate the testing landscape due to their comprehensive urology departments and ability to handle complex diagnostic procedures. Diagnostic centers are focusing on specialized BPH screening services with faster turnaround times. Research institutes play a crucial role in developing novel testing methodologies and validating emerging diagnostic biomarkers. |
| By End User |
|
Men Aged 60-70 represent the primary demographic for BPH testing, as prostate enlargement symptoms typically manifest most prominently in this age group. Younger age groups (50-60) are increasingly being screened proactively, driven by greater health awareness. The over-70 segment requires the most frequent monitoring due to higher progression rates of urinary complications. |
| By Testing Approach |
|
Diagnostic Confirmation tests represent the largest procedural volume as physicians require multiple validation points before treatment decisions. Disease monitoring is growing in importance for tracking BPH progression in patients opting for watchful waiting approaches. Initial screening is being increasingly integrated into routine men's health checkups, particularly for high-risk patients. |
| By Technology |
|
Conventional Methods like digital rectal exams and PSA tests still form the testing foundation, but advanced ultrasound and cystoscopy techniques are gaining adoption for their enhanced accuracy. Emerging biomarker research is focused on developing genetic and molecular profiling tests that could enable earlier disease detection and personalized treatment pathways. |
Innovative Diagnostics and Treatment Solutions Driving Market Growth
The benign prostatic hyperplasia testing market is characterized by the presence of established pharmaceutical giants and specialized diagnostic companies. Astellas Pharma and Eli Lilly and Company dominate the therapeutic segment with FDA-approved medications, while diagnostic companies like Nymox Pharmaceutical Corporation lead in developing innovative testing solutions. Market consolidation is increasing as larger players acquire niche diagnostic technology providers.
Several emerging companies are making significant strides in developing novel testing methodologies. Protox Therapeutics and Quest PharmaTech are pioneering advanced urodynamic testing systems, while AEternaZentaris focuses on next-generation PSA tests. Regional players in Asia and Europe are gaining traction by offering cost-effective testing solutions, creating a competitive environment that drives continuous innovation in diagnostic accuracy and patient comfort.
List of Key Benign Prostatic Hyperplasia Testing Companies ProfiledAstellas Pharma Inc.
AEterna Zentaris Inc.
Nymox Pharmaceutical Corporation
Protox Therapeutics Inc.
Quest PharmaTech Inc.
Siemens Healthineers
Abbott Laboratories
Beckman Coulter Inc.
Danaher Corporation
Sysmex Corporation
bioMrieux SA
The global Benign Prostatic Hyperplasia (BPH) testing market is valued at millions in 2024, with projections reaching significant growth by 2031. The increasing geriatric male population remains a primary driver, as BPH predominantly affects men over 50. With aging populations worldwide, especially in developed nations, demand for accurate diagnostic solutions continues to rise steadily.
Other TrendsAdvancements in Diagnostic Technologies
Traditional PSA blood tests are being supplemented by more accurate diagnostic methods like urodynamic testing and cystoscopy. Novel testing approaches that reduce false positives and improve early detection are gaining traction, with market segment percentages showing increased adoption of these advanced techniques by 2026.
Regional Market Growth PatternsNorth America currently leads the BPH testing market due to advanced healthcare infrastructure and high awareness. However, Asia-Pacific is expected to show the highest CAGR during the forecast period, driven by improving healthcare systems, growing medical tourism, and increasing governmental healthcare expenditure in countries like China and India.
Competitive Landscape Shifts
Key players including Astellas Pharma and Eli Lilly are focusing on strategic partnerships and technological innovations. Market analysis shows the top five companies held substantial revenue share in 2024, with competition intensifying as new entrants develop more precise diagnostic solutions.
Expanding Application SectorsThe market is segmented into hospitals, diagnostic centers, clinics, and research institutes. Diagnostic centers are anticipated to experience the fastest growth, owing to increasing preference for specialized testing facilities and the rising trend of preventive healthcare among aging male populations.
Regional Analysis: Benign Prostatic Hyperplasia Testing MarketEurope
Europe represents the second largest market for BPH testing, characterized by standardized diagnostic protocols across EU countries. The region benefits from universal healthcare systems that incorporate routine prostate health screening for aging populations. Germany and France lead in adoption of advanced urodynamic testing systems, while cost-conscious markets emphasize basic PSA screening. Increasing focus on minimally invasive diagnostic techniques and growing awareness about BPH complications support market growth. Stringent EU medical device regulations however slow the introduction of novel testing technologies compared to North America.
Asia-Pacific
The Asia-Pacific BPH testing market shows the highest growth potential due to rapidly expanding healthcare infrastructure and increasing disease awareness. Japan and South Korea lead in technology adoption while China and India focus on expanding basic diagnostic access. Challenges include limited reimbursement for advanced testing and uneven distribution of urology specialists. The region sees growing investments in point-of-care testing solutions and telemedicine-based diagnostic consultations to address rural healthcare gaps.
Latin America
Latin America's BPH testing market is developing steadily, with Brazil and Mexico as key growth markets. Urban centers show better diagnostic availability but rural areas face significant infrastructure limitations. Public healthcare systems prioritize essential diagnostics while private hospitals adopt more advanced technologies. Economic volatility affects testing equipment procurement cycles, and the region relies heavily on imported diagnostic devices from North America and Europe.
Middle East & Africa
The MEA region presents a mixed landscape for BPH testing, with Gulf countries showing advanced diagnostic capabilities similar to Western markets while Sub-Saharan Africa faces severe resource constraints. The market is growing steadily in urban centers through hospital expansion projects and medical tourism development. However, cultural barriers to prostate health discussions and limited specialist availability remain significant challenges across most markets in the region.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252031. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research organizations
Investors, consultants, and policy makers
-> Global benign prostatic hyperplasia testing market was valued at USD 2.1 billion in 2024 and is projected to reach USD 3.2 billion by 2031.
-> Key players include AEternaZentaris, Astellas Pharma, Eli Lilly and Company, IntelGenx Technologies Corp, and Nymox Pharmaceutical Corporation, among others.
-> The market is projected to grow at a CAGR of 5.8% from 2025 to 2031.
-> North America currently dominates the market, while Asia-Pacific shows the highest growth potential.
-> Key drivers include rising prevalence of BPH among aging populations, advancements in diagnostic technologies, and increasing healthcare expenditure.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates